....conference. I am Andrew Tsai, Senior Biotech Analyst at Jefferies, and it is my pleasure to have Alisha Alaimo joining me today from Biogen, President, Head of North America. Welcome, Alisha.
Thank you.
Maybe to get started, Alisha, I have viewed Biogen as a $10 billion base business that is now growing thanks to the Apellis transaction. You have a whole suite of pipeline readouts coming up. As investors think about the growth profile of Biogen longer term, what products do you think could surprise to the upside?
Thank you for the question. Also, thank you for everyone that showed up in the room today. There is nothing like talking to an empty room, so I love seeing some good-looking faces, and for all of you that have dialed in, and thank you for inviting me here today. You are exactly right. Well, first of all, Biogen, I believe, is really at their turnaround point. If you think we have been in existence for almost 50 years, about four years ago when Chris Viehbacher started is really when the turnaround story started.
For any of you that dialed into any of the calls, we really put a lot of effort in reducing our cost base, right, reallocating our capital. We also cleaned up a lot of the operations that we had. We reprioritized our pipeline, which, by the way, that is why these next couple readouts become very important. That work started four years ago. On top of where are we going to put the money if we have to do any deals? In parallel to that, we've been in a very special situation where we've been doing. We had seven launches in seven years.
Not many companies can say that of our size. Because our size is really, I think, the sweet spot in the industry, you get very close and can do things very quickly with agility. When you see the market changing beneath our feet, which we've seen a lot of in the last couple years, especially with a lot of the government regulations and changes that are coming out, the question really becomes, can your teams move at the same speed that the market is moving? Because the market is now beating a lot of the organizations that you see.
As we look towards our readouts, which are very pivotal readouts for us, and we look at the future of the organization, commercial capabilities now in biopharma become so important. Because as you see drug launches, gone are the days that you just need a field force, you just need some access, and all of a sudden you hit $1 billion. You have to move with that speed. Because of those capabilities, you will see there are now proof points for our future products. If you look at MS, which was the melting iceberg that Chris so famously called it, you can see how resilient it's become.
Those capabilities we built with maintaining that business is what is going to make lupus and felzartamab and AMR and multiple indications very, very successful. In addition to that, when you look at the products in our portfolio, or if you look at the most recent acquisition with Apellis, I think everyone thought of Syfovre as a product that would constantly be declining. If you look at quarter three, I think it surprised a lot of people. That is due to commercial capabilities that we were able to put in place very quickly.
As we look forward to the company and as we look at the turnaround and getting back to revenue growth, which we, of course, want to grow next year, if Biogen grows next year, that will be the first time since 2019 that we've grown. A couple of the products to keep, I believe, your eyes on. First of all, Leqembi. I know in the beginning everyone wanted Leqembi to take off way faster than what it did. Of course, we did as well. But now that you see how difficult that market is, we're now at a point where you can expect quarter-over-quarter growth.
With the launch of Iqlik, we're seeing very interesting early signals where you have physicians who have never written Leqembi or Kisunla before writing IQLIK. You're also seeing switches from Kisunla to Iqlik. That is already laying the path that subq becomes a very important option for this patient population. I think Leqembi is one to keep an eye on. Another one, which not a lot of people ask about, but you'll probably go back and look at the numbers, is Zurzuvae for postpartum depression. If you look at the growth that we've had every single year, it's been quite impressive.
Very large market, very large runway. I don't spend a lot of money on Zurzuvae. However, this market has lots of tailwinds, especially with mothers. What you are going to see is this will also be a nice growth year-over-year for several years to come. If you look at Syfovre and Empaveli in the most recent deal, you will see that Empaveli is growing at a nice clip in an ultra-rare disease. In the quarter, one of the things that we did uncover once they were underneath our umbrella, C3G and IC-MPGN, the team has done a very good job of especially getting pediatrics and severe patients on product.
Where we were losing, though, was in PNH, and it is my understanding PNH was not actually discussed quite a bit. Literally within four weeks, we were able to identify the issue and baseline that. We stopped the bleeding, and we are already back to growth on PNH, which tells you how highly sensitive it is. Also with precision, if you go to the right physicians, you can actually turn it around. I think Empaveli is another one.
Last but not least, of course, is Syfovre. There is actually a very good runway there. We were very conservative with how we modeled this when we did the deal, but I think after you have seen a couple of quarters of growth, not just in volume, but also some of the things that we put in place, which are the Biogen rules on how you deal with free patients, how you ensure there is coverage, understanding how you compete in the market, you are starting to see that take place.
I think we have identified a couple other issues in geographic atrophy that we are going to be able to tackle quite quickly and over the next years, and I think you can also expect Syfovre to grow as well, which I think was probably not on anyone's dance card.
Very clear. Thanks. Very helpful. Maybe starting with Leqembi , just a couple questions. Now that you have the subq full at-home use, just feels like the world is your oyster a little bit here. What is the bottleneck left after? Let us just assume you did get payer access January 1st. What else is there in terms of volume?
I think subq, the interesting thing that we've noticed, it's really changed the convenience conversation. When you look at the market and people started looking at Leqembi versus Kisunla, the only reason for any of you who even go out and speak to physicians or talk to them, they will say, "We like the once-monthly dosing, and we like to know that we can potentially stop it if we think the plaques are cleared." We, of course, believe that Alzheimer's is a chronic disease.
It is something that you do need ongoing treatment for. Introducing subq, which is a stay-at-home option for these patients, has changed that convenience conversation. The fascinating thing that you see with IQLIK is that when we first introduced maintenance dosing with subq, the questions that we would have is, "Well, why don't I see subq flying off the shelf with maintenance?" In this therapeutic area, because the patients are older and many of the patients don't have a lot of activities outside of their home, going for an IV infusion gives them a sense of community.
They plan their appointments with the people that they've met while they've been there, and they get on a cadence where it becomes a social gathering for them. For that cohort of patients in the very beginning when they wanted subq, we learned they wanted it to go on cruises. Cruises apparently a very big thing in this age group, and man, do they love taking subq on their cruise and not having to come in for an IV. Now you go to Iqlik . For initiation, we are seeing everything happen across the board. We see Leqembi IV patients transitioning to Iqlik .
We see Kisunla IV transitioning. We see, as I said earlier, people who've never written the products start Iqlik. We're also seeing the Leqembi IV transitions as well, but we also see that they end up going back sometimes. The great thing is optionality in the younger patient cohort becomes increasingly important. If you think about the potential readout for the trial, like AHEAD 3-45 in the pre-symptomatic patient, those will be younger patients who are still working. They want to work for as long as they can. Subq becomes also a great option for them.
I see. When I think medium term, the industry's pursuing brain shuttles. How are you thinking about defending the Leqembi franchise? For instance, do you guys have a brain shuttle program that you're working on?
Thank you for the very direct question, Andrew. The brain shuttle data actually looks pretty impressive. I think now, and I am sure many of you followed BIIB080 and DIAN-TU readout, which today at CTAD, you are going to see some more data. If it has not happened in the headlines yet, I am sure it will come out. I would say keep an eye out on that for our anti-tau. We believe you are going to need multiple modalities as you look at this disease state. I think there are still so many questions that we still have yet to answer.
Even though the brain shuttle looks promising so far, it still remains to be seen on what happens once you go into these larger trials and once you read out in phase III. We look at, it is not so much defending, but how are we going to grow our Alzheimer's franchise? Clearly, both Leqembi and Kisunla have been great first options for, obviously, Alzheimer's disease. As you look at DIAN-TU, I think anti-tau, a lot of what we are seeing in the market is people used to be very black and white on, "I am an amyloid beta person," or, "I am an anti-tau person."
You are starting to see them now maybe put the weapons down and coming together saying, "This may be a multi-modality therapeutic area." There will be room for everything. As you look at brain shuttles for Biogen, we are looking at potential options in our preclinical stages.
Great. In the interest of time, I would like to jump actually to your pipeline. Just the elephant in the room, the SLE-2 data readouts in early December. That could really get the stock going, in my opinion, a big momentum play for next year. Just a housekeeping question. What should we expect in the press release in December? Do you plan to host a conference call? How detailed of a dataset should we be able to receive?
For SLE, we will have both trials by that point in time, and we have made a decision that we will announce the results once we have both trials in so we can analyze them. That will be done via a press release, and of course, we will give as much information as you can in a press release. We typically, by standard practice, do not do teleconferences, but anything could be possible. I know we always keep optionality for that as well, but typically it will just be the press release.
I think when you look at both SLE and CLE, the way in which we are planning commercially is obviously we are planning to hopefully win in both spaces. The commercial teams have planned for any or all options that could potentially happen depending on the readouts of all three of those trials, and we do find it a very exciting space to compete in.
In your view, ultimately, should you launch an SLE, what kind of efficacy safety profile do you think you need to show for you to take majority share? There are a couple of approved products and a third one entering the market soon.
I think when you look at the lupus segment, a lot of the pushback we get is, "Well, but Alisha, why have these other biologics not taken off?" I always kindly remind them, even if you are looking at $1.5 billion each for each product, for not being such a good launch, I would love another $1.5 billion product in my P&L. The fact of the matter is, it is a very difficult patient base. If you have ever met SLE patients, you have only ever met one, because every single one has such a different issue and problem. The biggest issue with SLE is that they are afraid of dying.
You know that is life-ending. When you talk to a physician, they will look at stable labs, and when you talk to a patient, they say, "But I am really sick. There's something wrong." They basically talk past each other because both are looking for very different expectations. When you look at the products that are on market today, there's a couple things. Number one, we've hired a team, and a lot of the individuals came from these organizations, so we have an idea of what's been invested in and what has not. I think with one of the products, it's a very slow onset, modest efficacy.
Another product, there is this fear of an infection risk that can happen. Both of those things become troublesome for HCPs, and they think, "Until it gets really, really, really bad, maybe I will reserve them." I think a regulatory approval already is a big win, and I think anyone would say that with as many failed trials that have happened in SLE. More importantly, patients want something, and so do physicians, that work fast. They don't have to worry about infection risk.
Obviously, you need to have coverage, and they want to know that it is doing something to make them feel, as they say, normal again. I use normal because normal for every patient is different. People will ask a lot about the SRI-4 endpoints. That is not how physicians actually look at patients in the clinic. They listen to what the feedback is from the patients, and then they decide what to do.
I believe with the fact that Biogen has gotten very good at deep insight research, we understand the barriers that the rheumatologists have in treating, and we understand the fears and why patients need to receive treatment. We know how to activate both simultaneously, which no other company has done in this space. Keep in mind, 75% of the patients are diagnosed sitting with a rheumatologist, and we know where they're at. It's a very well-defined market. If you put the right measures into place at launch, you will be able to capture them.
Very clear. When you top-line the results in December, would you guys be prepared to say, "Oh, we're filing," for instance? Do you wait for the CLE data in first half 2027? Is there a strategy around that?
Again, it depends on the data, and CLE is right around the corner. It is the very beginning of next year. Also, keep in mind, they go through two different regulatory paths anyway, and we will keep options open for any of the possibilities. We want it approved as quickly as possible, as I think patients, physicians, and shareholders would want as well. We will do what we believe is right for the community at large.
Of course. How aggressive are you hiring right now, or is that something you are waiting until the results? When we think about the launch, is it really about sales reps, or is it something else to drive momentum?
In the beginning of any pre-launch, it is really all about the medical teams, and it is how do you right-size them. You never want to spend too much money upfront because that money could be going towards other high ROI tactics that I am aware of for other brands that can give people a return in-year versus, quote-unquote, "wasting money." I would say that my team are masters at stage-gating. They are trained very well on when we should deploy and what the right moments are to deploy.
We use the medical teams to understand that, and then I stage-gate quite quickly. Even if I have positive trial results for SLE, I also still need to know CLE because I need to understand zip codes and how I want to place my reps. Will they call on both? Do you call on one? Do you hyper-focus on another? We have plans for every single scenario, but we will job post, but I will not be spending money until I know the full results of the three.
Makes sense. There is also dapirolizumab pegol that you are working on in SLE, phase III data in 2028. If both succeeded, how do you position both drugs exactly?
Again, depending on data and depending on what I can say about each product, dapirolizumab pegol is in an alliance with UCB. Being in alliance with UCB means I have a very hard firewall between both of these teams. What you will see is you will see that we will build both teams to win, no matter what the data says, other than we do need, obviously, a regulatory approval. Having two shots on goal is way better than just one in this space.
Dapirolizumab pegol has already proven to have some positive outcomes with especially fatigue that has caught the eye of many clinicians because fatigue is one of the number one things patients complain about. What you will see is that we would be building two teams in parallel.
Understood. SLE for litifilimab, again, December, CLE is first half. Which indication is easier to sell in your view?
Number one, depends on the data. Number two, both spaces are about the same potential size, right? So keep that in mind. You have 300,000 SLE patients, you have 250,000 CLE, 50,000 patients have both, which I will tell you, every CLE patient will say, "Please don't let me ever get SLE." It really is a devastating disease.
You are looking at the same total market as like an MS market. If you look at the takeoff of Benlysta and Saphnelo, and you chart them on a graph over the Avonex and interferons of MS, which keep in mind, one of my largest products is still an interferon in MS, where you have so many advanced medications today, you will see the actual takeoff and penetration of patients is the exact same as you see in lupus.
We do believe that lupus, as more products launch, will grow this market to about the same size as what you saw as peak in MS. If I were to take them separately, CLE looks like it could be a potential $6 billion-$8 billion market, and so does SLE. Both are quite large, even independently.
Okay. Well, good luck on the December readout.
Thank you.
Then there's also felzartamab in first half phase III data in AMR. I think you guys have estimated 11,000 U.S. patients out there. Are they all ready to go? Are they all diagnosed, to be clear, or is there some kind of patient finding work that you need to do?
I really love felzartamab, and I will tell you why. Felza for both AMR and MVI is a very near-term, concentrated, targeted, well-built-out area. If you look at AMR, we are aware of 11,000 patients being diagnosed. These patients get diagnosed, they get their transplant, they are with their transplant physician for a year. After they get their kidney for a year, they go back to their general nephrologist. AMR develops over a one to 10-year time period, so there is going to be patients that are still with the transplant, and you have others that are in gen neph.
This is where purchasing Apellis and getting Empaveli under our belts has been incredibly important. We already call on the gen nephs that cover off on the transplant patients, and you need a very small team to cover off on the transplant physicians. For the 11,000, as with any disease, keep in mind with AMR, if you get AMR, 75% of the patients lose their graft. They lose the kidney. It is one of the biggest fears you have outside of, "Will I ever get a kidney?" With that 75%, there is already a pretty well-defined diagnosis that happens with gen nephs, where they pass it on to the transplant physicians.
Transplant physicians are stewards of the graft. They want no one else touching their patients. They are very specific about what they take when it comes to medication because of the graft. They will be the sole prescribers of felza. It is getting the patients from gen neph into the transplant physicians to get treatment.
Some of those 11,000 that we know of as of today, which keep in mind, they fall out and more will come in, but for some of those 11,000, those patients will already be either on dialysis or on a wait list for a kidney. Those are not the patients we are targeting. We are doing the work right now to find out for the majority of those patients, where are they sitting? How quickly can we get them into the transplant centers?
Very clear. In the last couple minutes, maybe just to touch on salanersen, because the phase III data is in 2028, so good chain of catalysts. Ultimately, this feels like a shiny thing for your business. Maybe talk about why you think this could be a superior product compared to any SMA therapy out there.
SMA is one of probably the most special therapeutic areas I've ever worked in. The reason why is because the patients typically know about your clinical trial program than anyone else. They are constantly on top of the data, they work very closely with the patient advocacy group, and they know when products are coming long before most people do. Spinraza high dose, I think, is an excellent proof point for people. When you look at what we've done in less than a year to get patients transitioned, a lot of that was pull from the patients versus a push from the doctor.
We made it easy for the doctors to transition them, but almost every single patient wants to transition because they want more efficacy. With Spinraza high dose, what you've seen this year is not only did we maintain the patients, which if you look in past years, there's always a transition to a cohort of them to Evrysdi. There's always a decline depending on where you're at what point in the year. We've been able to hold patients, and we've also been able to prevent discons, so not just transitioning to a competitor product, but prevent discons.
For next year, and by the way, in this year, the first time we've dosed a newborn for three years. We have not dosed a newborn in three-year time period. This was the first time ever when Spinraza high dose came out. What are the questions we're asked all the time? Patients have been asking about salanersen ever since we came out with the trial data. Salanersen, if you look at our program, we have the most comprehensive SMA program out of any product in the space. Any question the doctor asks, "Can you use it after Evrysdi?
Can you use it after Spinraza? Can you use it instead of Zolgensma?" We've got every one of those trials already mapped out. At one dose annually, what we believe we will see is that not only will all of the Spinraza patients want to go over due to only having one intrathecal injection, you will now start seeing many patients in the SMA community coming back in to our therapeutic area in Spinraza salanersen than ever before, because our belief is that the benefit of this product will be well worth the dose.
Okay. I think that's all the time we have, Alisha.
Thank you, Andrew.